On September 27, 2022, the Cancer Research Institute of New York awarded the 2022 William B. Coley Award to four scientists, including Academician Shao Feng (co-founder of Yanming Biology), Harvard Medical School, Judy Lieberman and Hao Wu, and Genentech Vishva Dixit. Among them, Academician Shao Feng is the first scientist to win this honor based on original scientific discoveries made in China since 1979, and gave a keynote speech as the award-winning representative. The William B. Coley Award is the top prize in the oncology immunology. The award was established in 1975 to commemorate Dr. William Coley, a pioneer of tumor immunotherapy. The William Coley Award is reviewed by the New York Cancer Institute (CRI) and is awarded to outstanding scientists who have made significant contributions to the field of basic immunity and oncology immunology. Their scientific discoveries have given humans a deep understanding of the immune system, cancer and other diseases, and have promoted the development of a variety of therapies based on the human immune system.
Using the immune system to fight cancer is not a new concept that has only been born recently. More than 100 years ago, Dr. William Coley injected bacteria or bacterial products into cancer patients in order to enhance the activity of the immune system and treat cancer. Some data show that William Coley has treated nearly 1,000 cancer patients in his 40-year medical career and is a well-deserved pioneer in cancer immunotherapy. Unfortunately, due to the technological level at that time, the concept of immunotherapy pioneered by William Coley was too advanced, the efficacy was not stable enough, and it was not valued and promoted.
Now, after years of research and development and the efforts of many scientists, tumor immunotherapy has become the most important field in tumor research. Many drugs that regulate the patient's immune system for tumor treatment have been approved for marketing. The William Coley Award, the award for basic immunology and tumor immunology named after William Coley, has also become one of the most important awards in the field of immunology. Among the scientists who won the William Colei Prize, several have won the Nobel Prize so far. Ralph M. Steinman, Jules A. Hoffmann, and Bruce A. Beutler, the 2011 Nobel Prize in Physiology or Medicine, won the award in 1998, 2003 and 2006, respectively; James P. Allison and Tasuku Honjo won the William Colei Prize in 2005 and 2014, respectively, and won the Nobel Prize in Physiology or Medicine in 2018. Chinese scientist Chen Lieping from Yale University , won the William Coley Award in 2014 for his outstanding contribution to PD-1/PD-L1 signaling pathway; Chen Zhijian from Southwest Medical Center in the United States won the award in 2020 for his outstanding contribution to cGAS-STING signaling pathway.
Academician Shao Feng won the 2022 William Coley Award for his original discovery in the field of pyroptosis. Shao Feng’s laboratory revealed the molecular mechanisms in which GSDMD is used as an inflammatory caspase substrate to perform pyroptosis for the first time in the world. In the past 10 years of research, the mechanisms of other proteins GSDME and GSDMB of this family have been gradually elucidated. Based on the immune activation characteristics of cell pyroptosis, a conceptual framework for improving anti-tumor immune activity through cell pyroptosis has also been pioneered. These works not only redefine the biological concept of pyroptosis, but also profoundly change everyone's traditional understanding of programmed cell death. Based on Shao Feng's important original discoveries in the fields of cell pyroptosis and tumor immunization , Yanming Bio has carried out a series of new drug research and development projects for inflammatory diseases and tumors by regulating cell pyroptosis by using small molecules and biological genes. At present, many projects have made breakthrough progress.
Yanming Bio is a company that settled in Zhongguancun Life Science Park ,
Zhiheng Direct Investment Fund and cooperative sub-fund Fengrui Capital
1.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-